Financial Perspectives Objectives Measures Targets Initiatives Financial • Increase

600 Words3 Pages
Financial Perspectives Objectives Measures Targets Initiatives Financial • Increase profitability. • Increase company revenue. • Reduce company costs. • Compare Company profits against previous years accounts. • Compare company expenses against previous years accounts. • Compare company expenses against previous years accounts. • $23bn by end of 2014. • $54.6bn - $57.2bn by end of 2014. • $43.4bn by end of 2013. • Diversification, by purchasing Icagen Inc. • Promoting product deals through price reductions. • Spinoff of 83% interest in Zoetis. Closed Kent, R&D. Customers • Improve consumer satisfaction. • Improve accessibility of information to consumers. • Increase in customer base. • % Of customer complaints. • % Of customer usage.…show more content…
1. These forecasts for 2013/2014 have been identified within the financial accounts of Pfizer for 2012/2013. 2. In order to reduce research and development costs, Pfizer closed down their research facility in Sandwich, Kent, United Kingdom, in early 2012. It also relinquished 83% of its animal care unit, zoetis. 3. Pfizer has responded to its reduced reputation due to $2.3bn fine in 2009 over misleading brand information by producing bi-annual corporate responsibility reports thereby hoping to increase consumer trust. 4. Pfizer have launched ten new mobile sites in February 2013, which enables consumers to access the company brand websites with greater ease and experience on their mobile phones. The aim of being achieved at a good rate in which consumers are able to look up certain products they may require for any illnesses. 5. Following the sale of their baby food business to Nestle for $11.9bn in April 2012 and spinoff of its shareholding in Zoetis, the company is aiming to focus on their core business of pharmaceutical medicines and thereby improve market share. 6. With the acquisition of Wyeth, Pfizer was provided with an influx of 17 new drugs and vaccines including Effexor and Enbrel followed with the launch of five new drugs in 2013, such as Axitinib (for kidney cancer treatment); Tofacitinib (arthritis) and Prevnar (pneumonia), among others. These launches and influx should help Pfizer compete with more

More about Financial Perspectives Objectives Measures Targets Initiatives Financial • Increase

Open Document